MTOR and cardiac hypertrophy: In contrast, in a mouse model for NSML with the recurrent Ptpn11 variant p.(Tyr279Cys), inhibition of the PI3K-AKT-mTOR axis, either with the mTOR inhibitor rapamycin or the AKT inhibitor ARQ 092, demonstrated beneficial effects on cardiac hypertrophy [62,78].